Effect of raloxifene - A selective oestrogen receptor modulator - On kidney function in post-menopausal women with Type 2 diabetes: Results from a randomized, placebo-controlled pilot trial

Diabetic Medicine

Volumn 24, Issue 8, 2007, Pages 906-910

  Hadjadj, S ^a,b   Gourdy, P ^b,c   Zaoui, P ^d   Guerci, B ^e   Roudaut, N ^f   Gautier, J F ^g   Chabin, M ^a   Mauco, G ^a,b   Ragot, S ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c CHU RANGUEIL   (France)

^d GRENOBLE UNIVERSITY HOSPITAL   (France)

^e Ctr Hospitalier Univ de Nancy   (France)

^f BREST UNIVERSITY HOSPITAL   (France)

^g SAINT LOUIS HOSPITAL   (France)

Author keywords

Albumin : creatinine ratio; Diabetic nephropathy; Raloxifene; Randomized controlled trial; Selective oestrogen receptor modulator

Indexed keywords

ALBUMIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RALOXIFENE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; KIDNEY FUNCTION; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PILOT PROJECTS; PLACEBOS; POSTMENOPAUSE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 34447631180     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02165.x     Document Type: Article

References (20)

1. Pergener TV, Brancati FL, Whelton PK, Klag MJ. End-stage renal disease attributable to diabetes. Ann Intern Med 1994 121 : 912 918.
2. Marre M, Lievre M, Vasmant D, Gallois Y, Hadjadj S, Reglier J-C et al. on behalf of the DIABHYCAR (DIABetes H, microalbuminuria, CAdiovascular events and Ramipril) Study Group. Determinants of elevated urinary albumin excretion in the 4937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa. Diabetes Care 2000 23 : 40 48.
3. US Renal Data System. USRDS 2000 Annual Data Report. Bethesda, MD : National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000.
4. Lokkegaard E, Pedersen AT, Heitmann BL, Jovanovic Z, Keiding N, Hundrup YA et al. Relation between hormone replacement therapy and ischaemic heart disease in women: prospective observational study. Br Med J 2003 326 : 426.
5. Gooding KM, MacLeod KM, Spyer G, Ewings P, Tooke JE, Shore AC. Impact of hormone replacement therapy on microvascular function in healthy and Type 2 diabetic post-menopausal women. Diabet Med 2005 22 : 536 542.
6. Chin M, Isono M, Isshiki K, Araki S, Sugimoto T, Guo B et al. Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice. Am J Pathol 2005 166 : 1629 1636.
7. Cohen AM, Rosenmann E. Effect of the estrogen antagonist, tamoxifen, on development of glomerulosclerosis in the Cohen diabetic rat. Diabetes 1985 34 : 634 638.
8. Bauduceau B, Chatellier G, Cordonnier D, Marre M, Mimran A, Monnier L et al. Hypertension and diabetes. ALFEDIAM recommendations. Diabetes Metab 1996 22 : 64 76.
9. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 : 31 41.
10. Szekacs B, Vajo Z, Varbiro S, Kakucs R, Vaslaki L, Acs N et al. Post-menopausal hormone replacement improves proteinuria and impaired creatinine clearance in type 2 diabetes mellitus and hypertension. BJOG 2000 107 : 1017 1021.
11. Manning PJ, Sutherland WH, Allum AR, de Jong SA, Jones SD. HRT does not improve urinary albumin excretion in post-menopausal diabetic women. Diabetes Res Clin Pract 2003 60 : 33 39.
12. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M et al. for the Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in post-menopausal women. N Engl J Med 2006 355 : 125 137.
13. Mankhey RW, Bhatti F, Maric C. 17β-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol 2005 288 : 399 405.
14. Sibiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis 1995 25 : 515 533.
15. Gades MD, Stern JS, Van Goor H, Nguyen D, Johnson PR, Kaysen GA. Estrogen accelerates the development of renal disease in female obese Zucker rats. Kidney Int 1998 53 : 130 135.
16. Tomiyoshi Y, Sakemi T, Aoki S, Miyazono M. Different effects of castration and estrogen administration on glomerular injury in spontaneously hyperglycemic Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Nephron 2002 92 : 860 867.
17. Tonolo G, Ciccarese M, Brizzi M, Puddu L, Secchi G, Calvia P et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997 20 : 1891 1895.
18. Ahmed SB, Hovind P, Parving HH, Rossing P, Price DA, Laffel LM et al. Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy. Diabetes Care 2005 28 : 1988 1994.
19. Lovegrove AS, Sun J, Gould KA, Lubahn DB, Korach KS, Lane PH. Estrogen receptor α-mediated events promote sex-specific diabetic glomerular hypertrophy. Am J Physiol Renal Physiol 2004 287 : 586 591.
20. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001 345 : 910 912.